Privia Health Group, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $PRVA in the last 7 days.
No SEC Form 4 filings for $PRVA in the last 30 days.
See all $PRVA insider activity →Privia Health Group (NASDAQ:PRVA) said Dr. Opella Ernest will join its board of directors effective Sept. 1, 2026, and will serve on the Compliance Committee, according to the company’s press release. Ernest is President of HCSC Markets and previously held senior roles at HCSC. Privia operates networks in 25 states and DC, serving 6.1 million patients.
Privia Health Group, Inc. (PRVA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors Dr. Ernest brings significant value-based care and clinical expertise ARLINGTON, VA – August 18, 2026 – Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Opella E
Privia Health Group (Nasdaq: PRVA) appointed Opella Ernest, M.D. to its board effective Sept. 1, 2026, and named her to the Compliance Committee. Privia said she has 20+ years of healthcare executive experience, including President of HCSC Markets at Health Care Service Corporation. The company did not provide financial figures.
Recent PRVA coverage spans earnings, financial news and corporate actions.
Board and compliance-committee appointment is a governance signal but not a direct financial catalyst.
Board appointment with defined director cash retainer and $200,000 RSU grant date fair value is unlikely to drive near-term fundamentals, but can affect governance expectations.
Board appointment adds governance and clinical/value-based care expertise, but it is not a direct financial or operational catalyst.
Guidance-upbeat fundamentals are offset by potential Medicare Shared Savings Program reconciliation delays that could distort year-end free-cash-flow timing.
The article reinforces that investors are focused on cash-flow timing risk (CMS shared savings) and whether AI-driven efficiency can sustain margin expansion after an EPS miss.
AlphAI scores every news story that mentions PRVA with an AI model for sentiment and relevance, and aggregates insider trades from Privia Health Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Privia Health Group (NASDAQ:PRVA) said Dr. Opella Ernest will join its board of directors effective Sept. 1, 2026, and will serve on the Compliance Committee, according to the company’s press release. Ernest is President of HCSC Markets and previously held senior roles at HCSC. Privia operates networks in 25 states and DC, serving 6.1 million patients.
2 min readPrivia Health Group, Inc. (PRVA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors Dr. Ernest brings significant value-based care and clinical expertise ARLINGTON, VA – August 18, 2026 – Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Opella E
2 min readPrivia Health Group (Nasdaq: PRVA) appointed Opella Ernest, M.D. to its board effective Sept. 1, 2026, and named her to the Compliance Committee. Privia said she has 20+ years of healthcare executive experience, including President of HCSC Markets at Health Care Service Corporation. The company did not provide financial figures.
4 min readPrivia Health (PRVA) reported Q2 results and raised 2026 guidance on an Aug. 6 earnings call, citing growth in implemented providers, attributed lives, practice collections, and adjusted EBITDA. Management expects free cash flow conversion of 70% to 80% of adjusted EBITDA, citing potential CMS Medicare Shared Savings Program timing effects.
6 min readPrivia Health (PRVA) reported Q2 revenue of $632.6M, up 21.4% year over year and above analysts’ $597.2M estimate, but adjusted EPS was $0.19 versus $0.24 expected. Management cited provider signings and growth in value-based attributed lives. Analysts asked about CMS shared savings timing, margin outlook, practice collections, AI use, and acquisition integration.
6 min readPrivia Health Group (PRVA) shares rose 2.1% to $22.45 after its Q2 results. According to the company, Q2 revenue was $632.6m and adjusted EBITDA $37.4m. Management lifted full-year 2026 guidance, citing improving margins, while also flagging cash conversion dependence on MSSP settlements and execution risk in new states.
7 min readPrivia Health Group, Inc. shares fell after its Q2 2026 adjusted earnings missed expectations, according to coverage of the company’s Aug 6, 2026 earnings call. The stock was down about 12.9% on the day at $20.86 as of 11:51am EDT, reflecting investor reaction to the results.
1 min readPrivia Health Group (PRVA) reported double-digit growth in practice collections and EBITDA, citing strong provider and attributed lives growth. The company said margins expanded and it raised its 2026 outlook, supported by new market expansion, acquisition integration, and robust cash flow and balance sheet flexibility, according to its Q2 2026 audio transcript.
1 min readPrivia Health Group, Inc. (PRVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results – 2Q’26 Net Income of $9.0M, +236.7% from 2Q’25 – 2Q’26 Adjusted EBITDA of $37.4M, +29.1% from 2Q’25 – Full-Year 2026 Guidance Raised for All Key Financial Metrics ARLINGTON, VA – August 6, 202
6 min readPrivia Health Group (NASDAQ:PRVA) is set to report Q2 earnings Thursday. Last quarter it posted revenue of $603.8 million, up 25.8% year over year, beating revenue estimates, but missed EPS. For Q2, analysts expect revenue growth of 14.6%. The stock is down 12.5% over a month; average analyst price target is $31.89 versus $23.79.
3 min read
